title: Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials.
abstract: BACKGROUND
  Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are related conditions with similar clinical features of variable severity. The objective of this systematic review is to evaluate the benefits and harms of available interventions for HUS and TTP.
  
  
  METHODS
  MEDLINE (1966 to June 2006), EMBASE (1980 to June 2006), the Cochrane Central Register, conference proceedings, and reference lists were searched to find randomized controlled trials (RCTs) of any intervention for HUS or TTP in patients of all ages selected for inclusion for this systematic review.
  
  
  METHODS
  Trials that compared an intervention with placebo, an intervention with supportive therapy, or one or more different interventions for HUS or TTP.
  
  
  RESULTS
  For TTP trials, failure of remission at 2 weeks or less and at 1 month or longer, all-cause mortality rate, and relapse rate. For HUS trials, all-cause mortality, chronic reduced kidney function, and persistent proteinuria or hypertension at last follow-up.
  
  
  RESULTS
  For TTP in adults, we found 6 RCTs of 331 patients. Two trials compared plasma infusion with plasma exchange using fresh frozen plasma and showed failure of remission at 2 weeks (2 trials, 140 patients; relative risk, 2.87; 95% confidence interval, 1.41 to 5.84), and all-cause mortality (relative risk, 1.91; 95% confidence interval, 1.09 to 3.33) occurred more frequently in the plasma infusion group. Three trials compared plasma exchange using cryosupernatant plasma with plasma exchange using fresh frozen plasma, and a meta-analysis of these trials showed no difference. Seven RCTs in 476 young children with postdiarrheal HUS have been conducted. None of the evaluated interventions (fresh frozen plasma transfusion, heparin with or without urokinase or dipyridamole, Shiga toxin-binding protein, and steroid) were superior to supportive therapy alone for any outcomes.
  
  
  CONCLUSIONS
  Limitations of this review include the small number and suboptimal quality of reporting of included trials, possibility of publication bias, small number of participants with atypical HUS, and failure to report results for patients with atypical and typical HUS separately.
  
  
  CONCLUSIONS
  No additional therapy has been shown to increase efficacy over plasma exchange for TTP. No intervention has been shown to be superior to supportive therapy in patients with postdiarrheal HUS.
authors.affiliation: Renal Section/Department of Pediatrics, Texas Children's Hospital/Baylor College of Medicine, Houston, TX, USA. mmichael@bcm.tmc.edu
authors.forename: Mini
authors.initials: M
authors.lastname: Michael
authors.forename: Elizabeth J
authors.initials: EJ
authors.lastname: Elliott
authors.forename: Jonathan C
authors.initials: JC
authors.lastname: Craig
authors.forename: Greta
authors.initials: G
authors.lastname: Ridley
authors.forename: Elisabeth M
authors.initials: EM
authors.lastname: Hodson
mesh_terms: D006463:Hemolytic-Uremic Syndrome / Q000628:therapy*; D006801:Humans; D010951:Plasma Exchange; D011697:Purpura, Thrombotic Thrombocytopenic / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic